Literature DB >> 1693009

Idiopathic polypoidal choroidal vasculopathy (IPCV).

L A Yannuzzi1, J Sorenson, R F Spaide, B Lipson.   

Abstract

Eleven patients, 40 to 71 years old, had a choroidal vasculopathy that led to hemorrhagic and exudative macular degeneration. The patients had peculiar polypoidal, subretinal, vascular lesions associated with serious and hemorrhagic detachments of the retinal pigment epithelium. This macular disorder, which we have named idiopathic polypoidal choroidal vasculopathy (IPCV), appears to represent a distinct entity that differs clinically and demographically from age-related macular degeneration (AMD) and other macular diseases associated with subretinal neovascularization. Recognition of this condition is important because it may have specific risk factors, natural course, and management considerations that differ from those of age-related macular degeneration.

Entities:  

Mesh:

Year:  1990        PMID: 1693009

Source DB:  PubMed          Journal:  Retina        ISSN: 0275-004X            Impact factor:   4.256


  253 in total

1.  Repeatability and reproducibility of manual choroidal volume measurements using enhanced depth imaging optical coherence tomography.

Authors:  Jay Chhablani; Giulio Barteselli; Haiyan Wang; Sharif El-Emam; Igor Kozak; Aubrey L Doede; Dirk-Uwe Bartsch; Lingyun Cheng; William R Freeman
Journal:  Invest Ophthalmol Vis Sci       Date:  2012-04-24       Impact factor: 4.799

2.  Association of ARMS2/HTRA1 variants with polypoidal choroidal vasculopathy phenotype in a Korean population.

Authors:  Dong Ho Park; In Taek Kim
Journal:  Jpn J Ophthalmol       Date:  2011-09-29       Impact factor: 2.447

3.  Treatment of polypoidal choroidal vasculopathy by intravitreal injection of bevacizumab.

Authors:  Akitaka Tsujikawa; Sotaro Ooto; Kenji Yamashiro; Hiroshi Tamura; Atsushi Otani; Nagahisa Yoshimura
Journal:  Jpn J Ophthalmol       Date:  2010-08-11       Impact factor: 2.447

4.  Polymorphisms in the VEGF-A in polypoidal choroidal vasculopathy in a Korean population.

Authors:  Dong Ho Park; In Taek Kim
Journal:  Jpn J Ophthalmol       Date:  2012-02-04       Impact factor: 2.447

5.  Baseline polyp size as a potential predictive factor for recurrence of polypoidal choroidal vasculopathy.

Authors:  Hae Min Kang; Hyoung Jun Koh; Sung Chul Lee
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2015-12-21       Impact factor: 3.117

6.  Subfoveal choroidal thickness in polypoidal choroidal vasculopathy after switching to intravitreal aflibercept injection.

Authors:  Masaaki Saito; Mariko Kano; Kanako Itagaki; Shigeyuki Ise; Kimihiro Imaizumi; Tetsuju Sekiryu
Journal:  Jpn J Ophthalmol       Date:  2015-09-09       Impact factor: 2.447

7.  The origins of polypoidal choroidal vasculopathy.

Authors:  M Yuzawa; R Mori; A Kawamura
Journal:  Br J Ophthalmol       Date:  2005-05       Impact factor: 4.638

8.  Clinicopathological correlation of polypoidal choroidal vasculopathy revealed by ultrastructural study.

Authors:  A Okubo; M Sameshima; A Uemura; S Kanda; N Ohba
Journal:  Br J Ophthalmol       Date:  2002-10       Impact factor: 4.638

9.  Polypoidal choroidal vasculopathy in patients aged less than 50 years: characteristics and 6-month treatment outcome.

Authors:  Young Suk Chang; Jae Hui Kim; Jong Woo Kim; Tae Gon Lee; Chul Gu Kim; Sung Won Cho
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2015-09-19       Impact factor: 3.117

10.  Polypoidal choroidal vasculopathy in elderly Chinese patients.

Authors:  Feng Wen; Changzheng Chen; Dezheng Wu; Haitao Li
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2004-06-29       Impact factor: 3.117

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.